Commercial Eyes

What Commercial Eyes does

Commercial Eyes is an Australian pharmaceutical and medical device commercialisation consultancy founded in 2001/2002 by Andrew Carter and headquartered in Melbourne, with a Sydney office and New Zealand operations through its subsidiary Maxx Pharma NZ Limited. The firm serves more than 800 pharmaceutical, medical device, diagnostic, and consumer healthcare companies across Australia and New Zealand, offering an end-to-end services platform covering regulatory affairs, quality and compliance, patient safety and pharmacovigilance, medical information, market access and competitive intelligence, and patient support programs. Its regulatory practice completes more than 160 projects annually across diverse therapy areas and is distinguished by its status as the only pharmaceutical professional services provider in Australia and New Zealand to have been audited by the US FDA with zero written 483 observations.

The company monetises through project-based professional services engagements delivered on a quote-by-quote basis, with no publicly disclosed pricing. Its technical stack includes Lorenz docuBridge for eCTD dossier publishing—a tool also used by the TGA—and two proprietary data assets: the TRoVE database (transfer-of-value competitive intelligence sourced from Medicines Australia transparency data) and MAP Insights (PBS item pricing analytics). Distribution is direct enterprise field sales to life sciences clients, supported by content marketing through blogs, newsletters, industry events (ARCS, ISPOR, BioMelbourne Network), and PR in trade publications such as PharmaDispatch.

In February 2024, Commercial Eyes was acquired by ProductLife Group, a multinational pharmaceutical and medical device consultancy, becoming a wholly-owned subsidiary that retains its brand and leadership team. The acquisition extends PLG's APAC footprint and provides Commercial Eyes with access to a network spanning 50+ countries directly and 150+ countries through global partners, while the firm continues to position itself as Australia's leading commercialiser of therapeutic goods.

Name

Commercial Eyes

Legal name

Commercial Eyes Pty Ltd

Website

https://commercialeyes.com.au

Company type

Private

Founded year

2002

Operating status

Acquired

Headcount range

51–100 employees

Short description

Commercial Eyes is an Australian pharmaceutical and medical device commercialisation consultancy serving 800+ life sciences clients with end-to-end regulatory affairs, pharmacovigilance, market access, and patient program services. Founded in 2001 and acquired by ProductLife Group in 2024.

Ownership category

akta.pro rank

Product category

Pharmaceutical and Medical Device Regulatory Consulting

NAICS

Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Safety & Medical Contact Centers (AE Intake/Call Centers) (HLAGALAI)

akta.pro secondary industry

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Pharmaceutical regulatory consulting
• Medical device commercialization
• Pharmacovigilance services
• Market access consulting
• Regulatory affairs services

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Consulting and Professional Services: Project-based consulting services providing end-to-end expertise across regulatory affairs, quality and compliance, patient safety, medical information, access and intelligence, and patient programs for pharmaceutical and medical device companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Commercial Eyes is an Australian pharmaceutical and medical device commercialization consultancy delivering end-to-end consulting expertise across six core service lines: Regulatory, Quality & Compliance; Quality & Compliance; Access, Research & Intelligence; Patient Safety & Risk Management (pharmacovigilance); Medical Information; and Patient Programs. Services span new product applications, lifecycle maintenance, GMP and quality management, adverse event reporting, QPPV provision, health technology assessment, pricing strategy, market access, and patient support programs for pharmaceutical, biotech, MedTech, diagnostic, and consumer healthcare clients in Australia and New Zealand.

Product overview

Commercial Eyes is Australia's leading pharmaceutical and medical device commercialisation consultancy offering end-to-end expertise across the full product lifecycle. The company operates as a unified services platform comprising six core service lines: Regulatory, Quality & Compliance Services (covering new product applications, lifecycle maintenance, and QMS); Patient Safety & Risk Management Services (pharmacovigilance, adverse event reporting, QPPV services); Medical Information Services (enquiry handling, medical communications); Patient Programs (compassionate access, patient support programs, managed access programs); and Access, Research & Intelligence Services (market access, pricing strategy, HTA, competitive intelligence). Additional offerings include Release for Supply (RFS) services, overseas GMP audit support, and TGA CPPs support. The company also operates Maxx Pharma NZ Limited as a subsidiary brand providing sponsorship/MAH services in New Zealand, and offers the proprietary TRoVE competitive intelligence database. All services leverage specialist tools including Lorenz docuBridge for regulatory dossier publishing. Commercial Eyes was acquired by ProductLife Group, expanding its footprint in the APAC region.

Differentiator

Problem solved

Functional benefit

Brands

• Maxx Pharma NZ Limited: A dedicated company offering sponsorship/Marketing Authorisation Holder (MAH) services for organisations looking to register and supply medicines, OTC products and medical devices in New Zealand.

Products and services

• Regulatory, Quality & Compliance Services Comprehensive regulatory affairs services including new product applications, lifecycle maintenance, compliance activities for prescription, over-the-counter, and complementary medicines, medical devices, cosmetics, food products, and quality management systems. The team completes over 160 projects annually across diverse therapy areas.
• Quality & Compliance Services Quality and compliance consulting services to ensure pharmaceutical, medical device, and healthcare companies meet regulatory requirements and maintain fit-for-purpose Quality Management Systems (QMS).
• Access, Research & Intelligence Services Market access services including pricing strategy, health technology assessment, health economics and outcomes research, market insights, portfolio pricing reviews, and competitive intelligence for pharmaceutical, biotech, and MedTech products in Australia and New Zealand.
• Patient Safety & Risk Management Services Pharmacovigilance and patient safety services including adverse event reporting, risk management programs, Qualified Person for Pharmacovigilance (QPPV) services, TGA pharmacovigilance inspection readiness, and safety and vigilance compliance.
• Medical Information Services Medical information management services including responding to healthcare professional and patient enquiries, medical communications, adverse event reporting, and post-pandemic digital engagement strategies for medical information.
• Patient Programs Comprehensive patient support and access programs including compassionate access programs, patient access programs, product familiarisation programs, patient support programs (PSPs) with nurse support, and managed access programs (MAPs) to facilitate deferred or cost-free access to medicines.
• Release for Supply (RFS) Services Batch release for supply services ensuring compliant and efficient release of pharmaceutical products for the Australian market, combining global GMP expertise with TGA regulatory knowledge.
• Overseas GMP Audit Support Expert overseas Good Manufacturing Practice (GMP) audit support services helping organisations meet vendor assurance requirements and manage risks across international manufacturing sites.
• Maxx Pharma NZ Limited Sponsorship Services A dedicated New Zealand-based subsidiary company offering sponsorship and Marketing Authorisation Holder (MAH) services for organisations looking to register and supply medicines, over-the-counter products, and medical devices in New Zealand.
• TRoVE (TRansfer of ValuE) Database A proprietary competitive intelligence database providing actionable insights from Medicines Australia transparency data, enabling clients to access competitive landscape information and market intelligence.
• TGA CPPs Support Services Services supporting the use of TGA Certificates of Pharmaceutical Products (CPPs) for international medicine registrations, providing regulatory credibility and flexibility across global markets.

Quantifiable outcome

• 160+ projects completed annually by Regulatory, Quality and Compliance team across diverse therapy areas
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• ProductLife GroupcoreStrategic or Co-development Partner · 1 January 2024ProductLife Group acquired Commercial Eyes in 2024, expanding its footprint in the APAC region. Commercial Eyes operates as part of ProductLife Group, a multinational organisation providing pharmaceutical and medical device consulting services across more than 50 countries with its own resources and 150+ countries through global network.
• ANDHealthcoreStrategic or Co-development PartnerCommercial Eyes is backing Australia's digital health vision through partnership with ANDHealth, supporting digital health innovation and commercialisation.
• Data OrganicasupportingStrategic or Co-development PartnerCommercial Eyes partners with Data Organica to blend traditional market research with digital behaviour analysis, providing comprehensive competitive intelligence combining digital footprints with behavioural psychology insights.
• Maxx Pharma NZ LimitedsupportingStrategic or Co-development PartnerSubsidiary company offering sponsorship/Marketing Authorisation Holder services for organisations looking to register and supply medicines, OTC products and medical devices in New Zealand.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ProductLife Group: Multinational pharma and medical device consultancy that acquired Commercial Eyes in 2024; operates in 50+ countries with regulatory, PV, market access, and quality services directly overlapping Commercial Eyes' full service stack at much larger scale.
• IQVIA: Global CRO and life sciences services platform; competes for the same pharma regulatory, pharmacovigilance, and market access budgets as Commercial Eyes, but as one offering within a much broader portfolio including clinical operations and real-world evidence.
• ICON plc: Global CRO with regulatory and pharmacovigilance capabilities alongside its core clinical research services; a broader incumbent that overlaps with Commercial Eyes' regulatory and PV practices from an enterprise-spend perspective.
• Parexel International: Large global CRO with regulatory, PV, market access, and consulting services; represents enterprise-spend competition where ANZ-related work gets bundled into wider global programmes.

Direct peers

• PharmaLex: Global provider of regulatory affairs, pharmacovigilance, quality, and market access consulting for pharma and medical device companies; closest direct competitor to Commercial Eyes' end-to-end commercialisation offering, with broader EU and US footprint.
• NDA Group: Independent regulatory and HTA consulting firm serving pharma and medical device sponsors globally; comparable to Commercial Eyes' regulatory, quality, and market access practices across prescription drugs, devices, and combination products.
• VCLS (Voisin Consulting Life Sciences): Independent consulting firm offering regulatory strategy, clinical development, and market access services; competitor for Commercial Eyes' regulatory lifecycle, HTA, and pricing engagements with biotech and medtech clients.

Regional players

• Novotech: APAC-focused clinical CRO headquartered in Sydney; regional peer with overlapping ANZ regulatory and clinical operations clients but stronger focus on biotech trial execution rather than commercialisation services.

Emerging players

• Clinipace Worldwide: Mid-sized CRO with regulatory and PV capabilities serving emerging biopharma; an emerging competitor for the same mid-size pharma and biotech mandates Commercial Eyes targets in regulatory and market access.

Others

• Charles River Associates (CRA Life Sciences): Management consulting firm with life sciences practice covering market access, pricing, and commercial strategy; adjacent competitor for Commercial Eyes' Access, Research & Intelligence engagements rather than its core regulatory work.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/commercial-eyes

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Commercial Eyes